MaxCyte has raised £40m (gross), c $55m, through an over-subscribed private placement of 5.74m new shares priced at 700p a share, a 4.5% premium to the closing price on February 2. Proceeds will strengthen MaxCyte’s balance sheet, supporting its leading position in the field of electroporation for cell-engineering and its growing stable of partnerships. MaxCyte’s ExPERT flow electroporation platform for non-viral delivery is increasingly playing an important enabling role in the development and manufacturing of many potentially transformative cell and gene therapies.
05 Feb 2021
US institutional private placing raises £40m
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
US institutional private placing raises £40m
MaxCyte, Inc. (MXCT:LON) | 313 -6.3 (-0.6%) | Mkt Cap: 325.9m
- Published:
05 Feb 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
MaxCyte has raised £40m (gross), c $55m, through an over-subscribed private placement of 5.74m new shares priced at 700p a share, a 4.5% premium to the closing price on February 2. Proceeds will strengthen MaxCyte’s balance sheet, supporting its leading position in the field of electroporation for cell-engineering and its growing stable of partnerships. MaxCyte’s ExPERT flow electroporation platform for non-viral delivery is increasingly playing an important enabling role in the development and manufacturing of many potentially transformative cell and gene therapies.